Addressing the Challenges of CNS Development

CNS programs can involve complex study designs, specialized assessments, challenging endpoints, and patient populations that can be difficult to recruit and retain. Novotech brings therapeutic and operational knowledge to help sponsors plan and deliver CNS studies across global markets.

  • Accelerate Development

    • Access to experienced CNS investigators, specialist sites, and patient populations to support efficient study execution.
    • Experience across all phases of development, from first-in-human studies through registration-enabling programs.
    • Global capabilities combined with strong regional expertise in key CNS research markets.
  • Navigate Complexity

    • Support for increasingly complex CNS programs across neurological, psychiatric, neuromuscular, and rare neurological disorders.
    • Expertise supporting complex study designs, cognitive assessments, functional endpoints, and patient-reported outcomes.
    • Experience supporting recruitment and retention strategies for complex CNS patient populations.
  • Advance with Confidence

    • A proven partner supporting CNS programs from early development through approval.
    • Integrated operational and regulatory support across major global markets.
    • Experience supporting therapies that have successfully advanced through clinical development and regulatory approval.
  • Early Development
    Through Approval

  • Global Regulatory &
    Operational Support

  • Therapies Reaching
    Patients

  • Quality & Compliance
    at Every Step

  • Scientific Excellence
    & Innovation

  • Data Integrity &
    Transparency

CNS Experience at a Glance

  • 265+

    Central Nervous System studies conducted

  • 400+

    Central Nervous System investigators and key opinion leaders engaged

  • 370+

    Central Nervous System sites activated globally

  • 30+

    Countries supporting Central Nervous System programs

  • 3700+

    Central Nervous System patients enrolled

  • 40+

    Central Nervous System indications supported

CNS Advantage

Advancing CNS Programs with Confidence

Integrated capabilities to support complex CNS development programs

Deep CNS Expertise

  • Therapeutic expertise spanning neurological and psychiatric disorders
  • Experience across neurodegenerative, psychiatric, rare neurological, and pain-related disorders
  • Support for complex study designs, functional assessments, cognitive endpoints, and ePRO / EDC-integrated outcomes
  • Experience across small molecules, biologics, gene therapies, and emerging CNS treatment approaches

Strategic Access to Patients and Research Networks

  • Established relationships with leading CNS investigators, specialist sites, and research networks
  • Access to diverse patient populations across major and emerging CNS trial-capable regions
  • Recruitment and retention strategies for complex CNS populations across all phases
  • Strong regional presence supporting CNS innovation and clinical research activity

Global Development and Regulatory Expertise

  • Integrated delivery model supporting regional and global CNS programs
  • Experience from early development through registration and post-marketing studies
  • across major development and emerging markets
  • supporting successful CNS development programs, including rare diseases

Indication Experience

Hover over each indication to explore conditions studied

 
  • Neuromuscular & motor neuron disorders Myasthenia Gravis, ALS, Muscular Dystrophy, Duchenne Muscular Dystrophy, Congenital Myasthenic Syndrome, Motor Neuron Disease, Myotonia Congenita, Spinal Muscular Atrophy, etc.

  • Movement disorders Parkinson Disease, Huntington Disease, Progressive Supranuclear Palsy, etc.

  • Psychiatric & neurodevelopmental disorders Bipolar Disorder, Depressive Disorder, Generalised Anxiety Disorder, Schizophrenia, Autism Spectrum Disorder, Developmental Speech / Developmental Disorder, etc.

  • Epilepsy & seizure disorders Epilepsy or Seizures, Dravet syndrome, etc.

  • Visual & retinal disorder Myopia, Presbyopia, Age-related Macular Degeneration, Macular Degeneration, Diabetic Retinopathy, Glaucoma, Inherited Retinal Disease, retinal/ocular disorders, etc.

  • Neurodegenerative & cognitive disorders Alzheimer Disease, Dementia, Mild Neurocognitive Disorder, etc.

  • Pain & headache disorders Migraine, Neuropathic Pain, Pain Disorders, Diabetic Polyneuropathy, etc.

  • Neuroinflammatory & demyelinating disorders Multiple Sclerosis, Chronic Inflammatory Neuropathy, Guillain-Barre Syndrome, etc.

  • Cerebrovascular disorders Stroke, etc.

  • Rare genetic / metabolic neurological disorders Adrenoleukodystrophy, Friedreich Ataxia, etc.

  • Other / unclassified Not Applicable, New Indication Request, Underproduction-related indication, etc.

 

Supporting Innovation in CNS Development

  • Neurodegenerative Disease Innovation

    • Disease-Modifying Therapies
    • Neuroprotective Approaches
    • Defined population targeted Therapies
    • Neuroinflammation-Targeted Therapies
  • Precision CNS Medicine

    • Biomarker Development and Guided Enrolment
    • Precision Medicine Strategies
    • Patient Stratification Approaches based on better understanding of pathogenesis
    • Digital Phenotyping to enable Early Detection and Precision Intervention
  • Advanced Therapeutic Approaches

    • Gene Therapies
    • Cell Therapies
    • RNA-Based Therapeutics
    • Next-Generation Sub-population targeted CNS Therapies

Meet Our CNS Experts

Our CNS specialists bring clinical and therapeutic knowledge across neurological and psychiatric conditions, with experience spanning study strategy, medical oversight, trial operations, and global development.